The global cancer/oncology drugs Market size was USD 154.47 billion in 2023, estimated at USD 172.39 billion in 2024 and is anticipated to reach around USD 507.68 billion by 2034, expanding at a CAGR of 11.41% from 2024 to 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cancer Drugs Market
5.1. COVID-19 Landscape: Cancer Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cancer Drugs Market, By Drug Class
8.1. Cancer Drugs Market, by Drug Class Type, 2024-2034
8.1.1. Targeted Therapy
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Chemotherapy
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Hormonal Therapy
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Immunotherapy
8.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Cancer Drugs Market, By Indication
9.1. Cancer Drugs Market, by Indication, 2024-2034
9.1.1. Lungs Cancer
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Colorectal Cancer
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Breast Cancer
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Liver Cancer
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Bladder Cancer
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Head & Neck Cancer
9.1.6.1. Market Revenue and Forecast (2021-2034)
9.1.7. Prostate Cancer
9.1.7.1. Market Revenue and Forecast (2021-2034)
9.1.8. Others
9.1.8.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Cancer Drugs Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.1.2. Market Revenue and Forecast, by Indication (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.1.3.2. Market Revenue and Forecast, by Indication (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Indication (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.2.2. Market Revenue and Forecast, by Indication (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.2.3.2. Market Revenue and Forecast, by Indication (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Indication (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Indication (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Indication (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.3.2. Market Revenue and Forecast, by Indication (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.3.3.2. Market Revenue and Forecast, by Indication (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Indication (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Indication (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Indication (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.4.2. Market Revenue and Forecast, by Indication (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.4.3.2. Market Revenue and Forecast, by Indication (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Indication (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Indication (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Indication (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.5.2. Market Revenue and Forecast, by Indication (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.5.3.2. Market Revenue and Forecast, by Indication (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Indication (2021-2034)
Chapter 11. Company Profiles
11.1. Amgen
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Bayer Healthcare AG
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. CELGENE CORPORATION
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. GlaxoSmithKline
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. ARIAD Pharmaceuticals, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Eli Lilly and Company
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Novartis
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Hoffmann-La Roche Ltd.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. AstraZeneca
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. BoehringerIngelheim GmbH
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample